2026-05-13T14:30:01-05:00 2025-06-30 390859910 BAKER TILLY ADVISORY GROUP LP 1570 FRUITVILLE PIKE SUITE 400 LANCASTER PA 17601 990 2024-07-01 210672684 CORIELL INSTITUTE FOR MEDICAL RESEARCH INC CORI 8567574846 403 HADDON AVENUE CAMDEN NJ 08103 DENISE L BUSCHER CFO 8567574846 2026-05-13 1 1 KERRI N BOGDA P00760402 7177404863 2026-05-13 2024 2025-03-06 01:10:19Z DR JEAN-PIERRE ISSA 403 HADDON AVENUE CAMDEN NJ 08103 25342150 0 X WWW.CORIELL.ORG X 1953 NJ GENERATE WORLD CLASS BIOMATERIALS AND CONDUCT GROUNDBREAKING RESEARCH. 18 15 155 15 0 0 8141077 1693929 23813715 23283009 147488 218313 2949 15145 32105229 25210396 32900 0 0 0 11853540 12192109 0 0 0 12308126 10903221 24194566 23095330 7910663 2115066 33636721 37747677 2999544 4794624 30637177 32953053 X CORIELL'S MISSION IS TO ACCELERATE SCIENTIFIC DISCOVERY BY GENERATING, BANKING, STORING AND DISTRIBUTING WORLD-CLASS BIOMATERIALS, AND CONDUCTING GROUNDBREAKING RESEARCH IN GENETICS AND EPIGENETICS. 0 0 18861446 0 23283009 THE CORIELL INSTITUTE FOR MEDICAL RESEARCH IS A WORLD-RENOWNED BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO PREVENTING AND CURING DISEASE. IN PURSUIT OF THIS MISSION, CORIELL SCIENTISTS CONDUCT GROUNDBREAKING RESEARCH IN RARE DISEASES, CANCER, AGING, INFECTIOUS DISEASES, AND PERSONALIZED MEDICINE.A GLOBALLY RECOGNIZED LEADER IN BIOBANKING, CORIELL HAS SERVED AS AN NIH-SUPPORTED CELL REPOSITORY FOR MORE THAN 50 YEARS AND CURRENTLY HOSTS BIOBANKS FOR SEVERAL NATIONAL INSTITUTES OF HEALTH (NIH) INSTITUTES, INCLUDING NIGMS, NINDS, NHGRI, NEI, AND NIA. CORIELL'S RESEARCH AND BIOBANKING PROGRAMS HAVE MADE IT ONE OF NEW JERSEY'S LEADING RECIPIENTS OF NIH FUNDING. IN ADDITION, CORIELL PROVIDES LABORATORY AND BIOBANKING EXPERTISE TO RESEARCHERS AND ORGANIZATIONS WORLDWIDE, SUPPORTING THE PROCESSING, STORAGE, AND DISTRIBUTION OF CRITICAL BIOLOGICAL SAMPLES.IN 2023, CORIELL PARTNERED WITH COOPER UNIVERSITY HEALTH CARE AND COOPER MEDICAL SCHOOL OF ROWAN UNIVERSITY TO ESTABLISH THE CAMDEN CANCER RESEARCH CENTER (CCRC), THE FIRST BASIC CANCER RESEARCH CENTER IN SOUTHERN NEW JERSEY.BUILDING ON ITS LEGACY OF SCIENTIFIC INNOVATION, CORIELL ANNOUNCED IN 2025 A PARTNERSHIP WITH THE NEW JERSEY ECONOMIC DEVELOPMENT AUTHORITY (NJEDA) TO LAUNCH A NEW STATE-DESIGNATED STRATEGIC INNOVATION CENTER (SIC). THE NEW JERSEY CORIELL LABS INNOVATION CENTER WILL BECOME THE LARGEST PUBLIC LIFE SCIENCES INCUBATOR IN THE REGION, SERVING AS A HUB FOR EMERGING BIOTECHNOLOGY COMPANIES AND FOSTERING COLLABORATION AMONG NEW JERSEY'S ACADEMIC, HEALTHCARE, AND RESEARCH INSTITUTIONS. 18861446 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 48 0 155 1 0 0 0 0 0 0 0 0 0 0 0 0 X 18 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NJ PA NY CA X HEATHER WHITE CONTROLLER 8567579738 403 HADDON AVENUE CAMDEN NJ 08103 DR JEAN-PIERRE ISSA PRESIDENT/CEO 40.00 0.00 X X 744131 0 48750 DENISE BUSCHER CFO 40.00 0.00 X X 226233 0 17016 LEO JOSE CIO & VP, INNOVATION 40.00 0.00 X X 239419 0 20453 ROBERT KIEP III CHAIR 1.00 0.00 X X 0 0 0 MARC MASER ESQ VICE CHAIR 1.00 0.00 X X 0 0 0 JOHN APATHY MBA TRUSTEE 1.00 0.00 X 0 0 0 ARNAUD BASTIEN MD TRUSTEE 1.00 0.00 X 0 0 0 LOU BEZICH MPP TRUSTEE 1.00 0.00 X 0 0 0 PETER DRISCOLL ESQ TRUSTEE 1.00 0.00 X 0 0 0 CHRISTOPHER GIBSON ESQ TRUSTEE 1.00 0.00 X 0 0 0 FRANK GIORDANO TRUSTEE 1.00 0.00 X 0 0 0 GENEROSA GRANA MD FACP TRUSTEE 1.00 0.00 X 0 0 0 MATTHEW HEWITT PHD TRUSTEE 1.00 0.00 X 0 0 0 JOHN PICCONE TRUSTEE 1.00 0.00 X 0 0 0 ANNETTE REBOLI TRUSTEE 1.00 0.00 X 0 0 0 MIRUNA SASU PHD TRUSTEE 1.00 0.00 X 0 0 0 ROLAND SCHWARTING MD TRUSTEE 1.00 0.00 X 0 0 0 KENNETH SOMBERG MD MBA TRUSTEE 1.00 0.00 X 0 0 0 ANTONIO TILLIS PHD TRUSTEE (UNTIL 01/25) 1.00 0.00 X 0 0 0 EDWARD VINER MD TRUSTEE (UNTIL 12/24) 1.00 0.00 X 0 0 0 NAHID TURAN CHIEF BIOBANKING OFFICER 40.00 0.00 X 213968 0 39573 JAROLAV JELINEK CHIEF SCIENTIFIC OFFICER 40.00 0.00 X 218226 0 23444 SHUMEI SONG PROFESSOR 40.00 0.00 X 219045 0 16570 NORA ENGEL ASSOCIATE PROFESSOR 40.00 0.00 X 140984 0 35823 RYAN CUNNINGHAM DIRECTOR, FINANCE 40.00 0.00 X 165528 0 26557 JIAN HUANG PROFESSOR 40.00 0.00 X 174792 0 31898 JOHN LU APPLICATION DEVELOPER 40.00 0.00 X 141759 0 18779 2484085 0 278863 28 0 1 0 VAN ANDEL INSTITUTE 333 BOSTWICK AVENUE NE GRAND RAPIDS MI 49503 NCI P50 SUBAWARD - RESEARCH/LAB WORK 719441 P AGNES INC 2101 PENROSE AVE PHILADELPHIA PA 19145 CONSTRUCTION SERVICES 603882 PEPPER ENVIRONMENTAL SERVICES 2251 FRALEY STREET PHILADELPHIA PA 19137 ENVIRONMENTAL SERVICES 430611 FEDEX PO BOX 371461 PITTSBURGH PA 152507461 SHIPPING SERVICES 377326 WASHINGTON UNIVERSITY IN ST LOUIS PO BOX 7412055 CHICAGO IL 606742055 RESEARCH/LAB WORK 312023 17 1994 1661861 30074 1693929 GOVT FEES & CONTRACTS 621500 19812464 19812464 NON-GOVERNMENT REPOSITORY SERVICE 621500 3194348 3194348 INVESTIGATOR DIRECTED SCIENCE 621500 276197 276197 23283009 350067 350067 131754 -131754 -131754 -131754 REFUNDS & REIMBURSEMENTS 900099 15145 15145 15145 25210396 23283009 0 233458 X 1076208 1076208 7908798 6799897 1108901 600081 524635 75446 2020359 2020359 586663 82467 504196 75024 75024 150921 150921 120425 120425 2782336 2447304 335032 898443 884180 14263 3983487 3499310 484177 222973 90165 132808 1037493 881010 156483 LAB SUPPLIES 1632119 1632119 23095330 18861446 4233884 0 1277 1277 4872858 8277493 3649087 2940369 1546391 843837 306220 262978 61130 79075 485785 467261 40131469 29868886 10372200 10262583 3634129 4084212 8707644 10528592 33636721 37747677 1312967 1148847 51271 259960 1635306 3385817 2999544 4794624 X 21791875 24222113 8845302 8730940 30637177 32953053 33636721 37747677 X 2115066 340187 -139377 X 0 1 X 1 0 X 1087567 3217491 2510168 8141077 1693929 16650232 15576879 19900725 20786182 23813715 23293060 103370561 16664446 23118216 23296350 31954792 24986989 120020793 10000 10000 0 10000 10000 120010793 62800 83936 92716 147488 350067 737007 62800 83936 92716 147488 350067 737007 532774 77704 11087 2949 15145 639659 17260020 23279856 23400153 32105229 25352201 121397459 0.98860 0.00610 X SCHEDULE A, PART III, LINE 12, EXPLANATION OF OTHER INCOME: MISCELLANEOUS INCOME - 2020 AMOUNT: $ 532,774. 2021 AMOUNT: $ 77,704. 2022 AMOUNT: $ 11,087. 2023 AMOUNT: $ 2,949. REFUNDS REIMBURSEMENTS - 2024 AMOUNT: $ 15,145. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 120425 120425 22974905 23095330 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 67900 67400 115012 120425 370737 250000 250000 250000 250000 1000000 1500000 3634130 450083 4084213 3197157 436973 3634130 3387810 309347 500000 3197157 3188112 350000 -150302 3387810 1837972 855673 494467 3188112 0.54010 0.19990 0.26000 0 0 245000 245000 20960900 14046373 6914527 1725594 1676509 49085 17199975 14146004 3053971 10262583 USE OF RESEARCH FACILITY 5529487 SPLIT-INTEREST AGREEMENTS 564301 OTHER MISCELLANEOUS ASSETS 4181 PREPAID CAPITAL CONTRIBUTIONS 32863 RESTRICTED CASH 4397760 10528592 ADVANCES ON HAND 10127 HOLDING ACCOUNTS 432 DUE TO COLLABORATION PARTIES 3375258 3385817 X 26063481 340187 652275 -139377 853085 25210396 0 25210396 23747605 652275 652275 23095330 0 23095330 PART V, LINE 4: THE INSTITUTE'S ENDOWMENT FUNDS ARE USED TO SUPPORT THE SHORT AND LONG TERM GOALS OF THE INSTITUTE. PART X, LINE 2: THE INSTITUTE ACCOUNTS FOR UNCERTAINTY IN INCOME TAXES USING A RECOGNITION THRESHOLD OF MORE LIKELY THAN NOT TO BE SUSTAINED UPON EXAMINATION BY THE APPROPRIATE TAXING AUTHORITY. MEASUREMENT OF THE TAX UNCERTAINTY OCCURS IF THE RECOGNITION THRESHOLD HAS BEEN MET. MANAGEMENT DETERMINED THAT THERE WERE NO TAX UNCERTAINTIES THAT MET THE RECOGNITION THRESHOLD IN 2025 AND 2024. PART XI, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 41,771. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -181,148. EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 653419 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 1656685 MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 35465 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 131527 SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR, 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 13355 SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL, 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 10812 SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO, 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 8389 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICE SALES OF BIOMATERIALS 5658 0 0 0 0 0 0 2515310 0 2515310 0 0 0 0 0 0 PART I, LINE 2: GRANT FUNDS FOR THE SUB-AWARDS WERE MONITORED THROUGH THE USE OF REPORTS PROVIDED BASED UPON THE WORK PERFORMED. X X 1 1 X X X X 0 0 0 0 0 0 0 1 0 DR JEAN-PIERRE ISSA PRESIDENT/CEO 624455 0 114508 0 5168 0 24150 0 24600 0 792881 0 0 0 LEO JOSE CIO & VP, INNOVATION 228699 0 10000 0 720 0 16153 0 4300 0 259872 0 0 0 NAHID TURAN CHIEF BIOBANKING OFFICER 201289 0 10000 0 2679 0 14947 0 24626 0 253541 0 0 0 DENISE BUSCHER CFO 214290 0 10000 0 1943 0 14921 0 2095 0 243249 0 0 0 JAROLAV JELINEK CHIEF SCIENTIFIC OFFICER 205049 0 10059 0 3118 0 14497 0 8947 0 241670 0 0 0 SHUMEI SONG PROFESSOR 216031 0 0 0 3014 0 15070 0 1500 0 235615 0 0 0 JIAN HUANG PROFESSOR 148081 0 23993 0 2718 0 12531 0 19367 0 206690 0 0 0 RYAN CUNNINGHAM DIRECTOR, FINANCE 158261 0 5000 0 2267 0 11488 0 15069 0 192085 0 0 0 NORA ENGEL ASSOCIATE PROFESSOR 134391 0 1000 0 5593 0 10303 0 25520 0 176807 0 0 0 JOHN LU APPLICATION DEVELOPER 134608 0 5000 0 2151 0 9570 0 9209 0 160538 0 0 0 PART I, LINE 1A LEO JOSE, JAROSLAV JELINEK, JIAN HUANG AND SHUMEI SONG RECEIVED TAX GROSS-UP PAYMENTS RELATED TO SERVICE AWARDS AND BONUSES RECEIVED. ALL AMOUNTS ARE INCLUDED AS TAXABLE COMPENSATION. JAROSLAV JELINEK AND NAHID TURAN HAVE DISCRETIONARY SPENDING ACCOUNTS TO BE UTILIZED FOR BUSINESS PURPOSES ONLY AND FOLLOWING ALL NORMAL PURCHASING/TRAVEL POLICIES OF THE ORGANIZATION. THESE ACCOUNTS CANNOT BE USED FOR PERSONAL EXPENSES. PART I, LINE 7 THE COMPENSATION COMMITTEE DETERMINES BONUSES FOR OFFICERS AND KEY EMPLOYEES BASED UPON VARIOUS PERFORMANCE CRITERIA. PERFORMANCE CRITERIA ARE BASED ON VARIOUS OBJECTIVES, SOME OF WHICH ARE BASED ON BUSINESS/ FINANCIAL GOALS. OVERALL, THE PRIMARY OBJECTIVES ARE OPERATIONAL IN NATURE WITH CONSIDERATION GIVEN TO FINANCIAL OUTCOMES. FORM 990, PART VI, SECTION A, LINE 1A THERE ARE 9 BOARD MEMBERS ON THE EXECUTIVE COMMITTEE. WITH THE EXCEPTION OF THE PRESIDENT AND CEO, THE OTHER BOARD MEMBERS OF THE EXECUTIVE COMMITTEE ARE NON-EMPLOYED VOLUNTARY BOARD MEMBERS. THE EXECUTIVE COMMITTEE MAY ACT ON BEHALF OF THE BOARD OF TRUSTEES WHEN THE BOARD IS NOT IN SESSION. FORM 990, PART VI, SECTION B, LINE 11B THE CFO PERFORMS AN INITIAL REVIEW OF THE FORM 990. AFTER INTERNAL REVIEW, THE CFO WILL PROVIDE THE DRAFT FORM 990 TO THE AUDIT COMMITTEE. FOLLOWING THE REVIEW BY THE AUDIT COMMITTEE THE FORM IS DISTRIBUTED TO ALL CORIELL TRUSTEES BEFORE FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE CEO ANNUALLY DISTRIBUTES THE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH MEMBER OF THE BOARD OF TRUSTEES. EACH TRUSTEE MUST COMPLETE AND RETURN THE ANNUAL DISCLOSURE STATEMENT TO THE CEO ON A TIMELY BASIS. HE OR SHE MUST TIMELY INFORM THE CEO AND/OR THE COMMITTEE OF ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST OR OF ANY SITUATION WHICH MIGHT LEAD TO THE APPEARANCE OF A CONFLICT OF INTEREST. IN ADDITION, THE CHIEF FINANCIAL OFFICER (CFO) ANNUALLY DISTRIBUTES A COPY OF THE EMPLOYEE CONFLICT OF INTEREST POLICY AND DISCLOSURE STATEMENT TO EACH OFFICER, EXECUTIVE, AND APPROPRIATE EMPLOYEE. THESE EMPLOYEES ARE REQUIRED TO SUBMIT THE COMPLETED DISCLOSURE STATEMENT TO THE CFO AND DISCLOSE ANY POTENTIAL OR ACTUAL CONFLICT OF INTEREST. REPORTED CONFLICTS OF INTEREST ARE SHARED WITH THE EXECUTIVE COMMITTEE. ANY BOARD MEMBER WHO HAS A CONFLICT OF INTEREST IS EXCLUDED FROM VOTING ON ANY ISSUE INVOLVING THE CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 USING COMPARABILITY DATA SOURCED FROM AN INDEPENDENT ORGANIZATION, A BOARD OF TRUSTEES' COMPENSATION COMMITTEE REVIEWS THE PERFORMANCE AND ESTABLISHES THE ANNUAL COMPENSATION FOR THE CHIEF EXECUTIVE OFFICER. COMPENSATION DECISIONS ARE DETERMINED BY TAKING INTO CONSIDERATION THE FAIR MARKET RANGE FOR THE INDUSTRY. ALL COMMITTEE DISCUSSIONS ARE DOCUMENTED IN BOARD MINUTES. THE PRESIDENT DETERMINES THE COMPENSATION ANNUALLY FOR ALL OTHER EMPLOYEES, INCLUDING OFFICERS AND KEY EMPLOYEES, BASED ON PERFORMANCE APPRAISALS AND REVIEWS. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 2,369,357. MANAGEMENT AND GENERAL EXPENSES 90,392. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 2,459,749. ADMINISTRATIVE COSTS: PROGRAM SERVICE EXPENSES 77,947. MANAGEMENT AND GENERAL EXPENSES 244,640. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 322,587. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF SPLIT-INTEREST AGREEMENTS 41,771. CHANGE IN VALUE OF FUTURE BUILDING OCCUPANCY -181,148.